Pulike Biological Engineering - Asset Resilience Ratio

Latest as of September 2025: 17.82%

Pulike Biological Engineering (603566) has an Asset Resilience Ratio of 17.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pulike Biological Engineering short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥550.97 Million

≈ $80.62 Million USD Cash + Short-term Investments

Total Assets

CN¥3.09 Billion

≈ $452.33 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Pulike Biological Engineering's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603566 total assets.

Liquid Assets Composition Over Time

This chart breaks down Pulike Biological Engineering's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Pulike Biological Engineering to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥550.97 Million	17.82%
Total Liquid Assets	CN¥550.97 Million	17.82%

Asset Resilience Insights

Good Liquidity Position: Pulike Biological Engineering maintains a healthy 17.82% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Pulike Biological Engineering Industry Peers by Asset Resilience Ratio

Compare Pulike Biological Engineering's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%
Race Oncology Ltd AU:RAC	Biotechnology	78.11%

Annual Asset Resilience Ratio for Pulike Biological Engineering (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Pulike Biological Engineering.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	15.51%	CN¥480.33 Million ≈ $70.29 Million	CN¥3.10 Billion ≈ $453.22 Million	+3.01pp
2023-12-31	12.49%	CN¥407.58 Million ≈ $59.64 Million	CN¥3.26 Billion ≈ $477.36 Million	-7.92pp
2022-12-31	20.41%	CN¥691.36 Million ≈ $101.17 Million	CN¥3.39 Billion ≈ $495.56 Million	+16.96pp
2021-12-31	3.46%	CN¥75.00 Million ≈ $10.97 Million	CN¥2.17 Billion ≈ $317.29 Million	-9.63pp
2020-12-31	13.09%	CN¥265.48 Million ≈ $38.85 Million	CN¥2.03 Billion ≈ $296.88 Million	-3.45pp
2019-12-31	16.53%	CN¥315.00 Million ≈ $46.09 Million	CN¥1.91 Billion ≈ $278.83 Million	+1.03pp
2018-12-31	15.50%	CN¥295.00 Million ≈ $43.17 Million	CN¥1.90 Billion ≈ $278.48 Million	-23.29pp
2017-12-31	38.79%	CN¥700.20 Million ≈ $102.46 Million	CN¥1.81 Billion ≈ $264.14 Million	+9.14pp
2016-12-31	29.65%	CN¥515.00 Million ≈ $75.36 Million	CN¥1.74 Billion ≈ $254.15 Million	+3.05pp
2015-12-31	26.60%	CN¥400.00 Million ≈ $58.53 Million	CN¥1.50 Billion ≈ $220.04 Million	--

pp = percentage points

About Pulike Biological Engineering

SHG:603566 China Biotechnology

Market Cap

$522.60 Million

CN¥3.57 Billion CNY

Market Cap Rank

#12209 Global

#3580 in China

Share Price

CN¥10.32

Change (1 day)

+0.29%

52-Week Range

CN¥9.78 - CN¥14.44

All Time High

CN¥34.10